Acticam

Land: Europeiska unionen

Språk: engelska

Källa: EMA (European Medicines Agency)

Köp det nu

Bipacksedel Bipacksedel (PIL)
24-03-2021
Produktens egenskaper Produktens egenskaper (SPC)
24-03-2021

Aktiva substanser:

meloxicam

Tillgänglig från:

Ecuphar

ATC-kod:

QM01AC06

INN (International namn):

meloxicam

Terapeutisk grupp:

Dogs; Cats

Terapiområde:

Anti inflammatory and antirheumatic products

Terapeutiska indikationer:

Oral suspension:Dogs:Alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders.Solution for injection:Dogs:Alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders.Reduction of postoperative pain and inflammation following orthopaedic and soft-tissue surgery.Cats:Reduction of postoperative pain after ovariohysterectomy and minor soft-tissue surgery.

Produktsammanfattning:

Revision: 9

Bemyndigande status:

Withdrawn

Tillstånd datum:

2008-12-09

Bipacksedel

                                Medicinal product no longer authorised
14
B. PACKAGE LEAFLET
Medicinal product no longer authorised
15
PACKAGE LEAFLET:
ACTICAM 5 MG/ML SOLUTION FOR INJECTION FOR DOGS AND CATS
1.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF
THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH
RELEASE, IF DIFFERENT
Ecuphar NV
Legeweg 157-i
B-8020 Oostkamp
Belgium
2.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Acticam 5 mg/ml solution for injection for dogs and cats.
Meloxicam.
3.
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
Meloxicam 5 mg/ml.
Ethanol anhydrous 150 mg/ml.
4.
INDICATION(S)
Dogs:
Alleviation of inflammation and pain in both acute and chronic
musculo-skeletal disorders. Reduction
of post-operative pain and inflammation following orthopaedic and soft
tissue surgery.
Cats:
Reduction of post-operative pain after ovariohysterectomy and minor
soft tissue surgery.
5.
CONTRAINDICATIONS
Do not use in pregnant or lactating animals.
Do not use in animals suffering from gastrointestinal disorders such
as irritation and haemorrhage,
impaired hepatic, cardiac or renal function and haemorrhagic
disorders.
Do not use in cases of hypersensitivity to the active substance or to
any of the excipients.
Do not use in animals less than 6 weeks of age nor in cats of less
than 2 kg.
6.
ADVERSE REACTIONS
Typical adverse reactions of NSAIDs such as loss of appetite,
vomiting, diarrhoea, faecal occult blood,
lethargy and renal failure have occasionally been reported. In very
rare cases elevated liver enzymes
have been reported. In dogs, in very rare cases, haemorrhagic
diarrhoea, haematemesis and
gastrointestinal ulceration have been reported. In dogs, these side
effects occur generally within the
first treatment week and are in most cases transient and disappear
following termination of the
treatment but in very rare cases may be serious or fatal. In very rare
cases anaphylactoid reactions may
occur and should be treated symptomatically.
Medicinal product no longer authorised
16
If adverse reactions occur
                                
                                Läs hela dokumentet
                                
                            

Produktens egenskaper

                                Medicinal product no longer authorised
1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
Medicinal product no longer authorised
2
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Acticam 5 mg/ml solution for injection for dogs and cats.
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains:
ACTIVE SUBSTANCE:
Meloxicam 5 mg.
EXCIPIENTS:
Ethanol, anhydrous 150 mg.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Solution for injection.
A clear yellow solution.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs and cats.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Dogs:
Alleviation of inflammation and pain in both acute and chronic
musculo-skeletal disorders. Reduction
of post-operative pain and inflammation following orthopaedic and soft
tissue surgery.
Cats:
Reduction of post-operative pain after ovariohysterectomy and minor
soft tissue surgery.
4.3
CONTRAINDICATIONS
Do not use in pregnant or lactating animals.
Do not use in animals suffering from gastrointestinal disorders such
as irritation and haemorrhage,
impaired hepatic, cardiac or renal function and haemorrhagic
disorders.
Do not use in cases of hypersensitivity to the active substance or to
any of the excipients.
Do not use in animals less than 6 weeks of age nor in cats of less
than 2 kg.
Do not use an oral follow-up therapy using meloxicam or other NSAIDs
in cats, as no safe dosage for
repeated oral administration has been established.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
For post-operative pain relief in cats, safety has only been
documented after thiopental/halothane
anaesthesia.
Medicinal product no longer authorised
3
4.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
If side effects occur, treatment should be discontinued.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as
there is a potential risk of
increased renal toxicity.
Special precautions to be taken by the person administering the
veterinary medicinal product to
animals
Accidental self-injection may give rise to pain.
                                
                                Läs hela dokumentet
                                
                            

Dokument på andra språk

Bipacksedel Bipacksedel bulgariska 24-03-2021
Produktens egenskaper Produktens egenskaper bulgariska 24-03-2021
Offentlig bedömningsrapport Offentlig bedömningsrapport bulgariska 24-03-2021
Bipacksedel Bipacksedel spanska 24-03-2021
Produktens egenskaper Produktens egenskaper spanska 24-03-2021
Offentlig bedömningsrapport Offentlig bedömningsrapport spanska 24-03-2021
Bipacksedel Bipacksedel tjeckiska 24-03-2021
Produktens egenskaper Produktens egenskaper tjeckiska 24-03-2021
Offentlig bedömningsrapport Offentlig bedömningsrapport tjeckiska 24-03-2021
Bipacksedel Bipacksedel danska 24-03-2021
Produktens egenskaper Produktens egenskaper danska 24-03-2021
Offentlig bedömningsrapport Offentlig bedömningsrapport danska 24-03-2021
Bipacksedel Bipacksedel tyska 24-03-2021
Produktens egenskaper Produktens egenskaper tyska 24-03-2021
Offentlig bedömningsrapport Offentlig bedömningsrapport tyska 24-03-2021
Bipacksedel Bipacksedel estniska 24-03-2021
Produktens egenskaper Produktens egenskaper estniska 24-03-2021
Offentlig bedömningsrapport Offentlig bedömningsrapport estniska 24-03-2021
Bipacksedel Bipacksedel grekiska 24-03-2021
Produktens egenskaper Produktens egenskaper grekiska 24-03-2021
Offentlig bedömningsrapport Offentlig bedömningsrapport grekiska 24-03-2021
Bipacksedel Bipacksedel franska 24-03-2021
Produktens egenskaper Produktens egenskaper franska 24-03-2021
Offentlig bedömningsrapport Offentlig bedömningsrapport franska 24-03-2021
Bipacksedel Bipacksedel italienska 24-03-2021
Produktens egenskaper Produktens egenskaper italienska 24-03-2021
Offentlig bedömningsrapport Offentlig bedömningsrapport italienska 24-03-2021
Bipacksedel Bipacksedel lettiska 24-03-2021
Produktens egenskaper Produktens egenskaper lettiska 24-03-2021
Offentlig bedömningsrapport Offentlig bedömningsrapport lettiska 24-03-2021
Bipacksedel Bipacksedel litauiska 24-03-2021
Produktens egenskaper Produktens egenskaper litauiska 24-03-2021
Offentlig bedömningsrapport Offentlig bedömningsrapport litauiska 24-03-2021
Bipacksedel Bipacksedel ungerska 24-03-2021
Produktens egenskaper Produktens egenskaper ungerska 24-03-2021
Offentlig bedömningsrapport Offentlig bedömningsrapport ungerska 24-03-2021
Bipacksedel Bipacksedel maltesiska 24-03-2021
Produktens egenskaper Produktens egenskaper maltesiska 24-03-2021
Offentlig bedömningsrapport Offentlig bedömningsrapport maltesiska 24-03-2021
Bipacksedel Bipacksedel nederländska 24-03-2021
Produktens egenskaper Produktens egenskaper nederländska 24-03-2021
Offentlig bedömningsrapport Offentlig bedömningsrapport nederländska 24-03-2021
Bipacksedel Bipacksedel polska 24-03-2021
Produktens egenskaper Produktens egenskaper polska 24-03-2021
Offentlig bedömningsrapport Offentlig bedömningsrapport polska 24-03-2021
Bipacksedel Bipacksedel portugisiska 24-03-2021
Produktens egenskaper Produktens egenskaper portugisiska 24-03-2021
Offentlig bedömningsrapport Offentlig bedömningsrapport portugisiska 24-03-2021
Bipacksedel Bipacksedel rumänska 24-03-2021
Produktens egenskaper Produktens egenskaper rumänska 24-03-2021
Offentlig bedömningsrapport Offentlig bedömningsrapport rumänska 24-03-2021
Bipacksedel Bipacksedel slovakiska 24-03-2021
Produktens egenskaper Produktens egenskaper slovakiska 24-03-2021
Offentlig bedömningsrapport Offentlig bedömningsrapport slovakiska 24-03-2021
Bipacksedel Bipacksedel slovenska 24-03-2021
Produktens egenskaper Produktens egenskaper slovenska 24-03-2021
Offentlig bedömningsrapport Offentlig bedömningsrapport slovenska 24-03-2021
Bipacksedel Bipacksedel finska 24-03-2021
Produktens egenskaper Produktens egenskaper finska 24-03-2021
Offentlig bedömningsrapport Offentlig bedömningsrapport finska 24-03-2021
Bipacksedel Bipacksedel svenska 24-03-2021
Produktens egenskaper Produktens egenskaper svenska 24-03-2021
Offentlig bedömningsrapport Offentlig bedömningsrapport svenska 24-03-2021
Bipacksedel Bipacksedel norska 24-03-2021
Produktens egenskaper Produktens egenskaper norska 24-03-2021
Bipacksedel Bipacksedel isländska 24-03-2021
Produktens egenskaper Produktens egenskaper isländska 24-03-2021
Bipacksedel Bipacksedel kroatiska 24-03-2021
Produktens egenskaper Produktens egenskaper kroatiska 24-03-2021

Sök varningar relaterade till denna produkt

Visa dokumenthistorik